Cargando…

Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan

Taiwan TB contact cohort: 0.5% 1-year yield, age ≥65 as significant risk factor and elevated TB risk at 5th year http://ow.ly/9ZGr30dpkMc

Detalles Bibliográficos
Autores principales:	Lee, Meng-Rui, Ho, Cheng-Maw, Lee, Chih-Hsin, Lee, Ming-Chia, Chang, Lih-Yu, Yu, Kai-Lun, Ko, Jen-Chung, Wang, Jann-Yuan, Wang, Jann-Tay, Lee, Li-Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2017
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593384/ https://www.ncbi.nlm.nih.gov/pubmed/28838982 http://dx.doi.org/10.1183/13993003.00851-2017

Ejemplares similares

Global reporting on tuberculosis preventive treatment among contacts
por: Falzon, Dennis, et al.
Publicado: (2022)

The potential impact of COVID-19-related disruption on tuberculosis burden
por: McQuaid, C. Finn, et al.
Publicado: (2020)

Insight into the impact of the COVID-19 epidemic on tuberculosis burden in China
por: Chen, Hongguang, et al.
Publicado: (2020)

Impact of metformin use among tuberculosis close contacts with diabetes mellitus in a nationwide cohort study
por: Lee, Ming-Chia, et al.
Publicado: (2019)

Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6–9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan
por: Wang, Jann-Yuan, et al.
Publicado: (2015)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

On tuberculosis and COVID-19 co-infection
por: Tadolini, Marina, et al.
Publicado: (2020)

Practices of therapeutic drug monitoring in tuberculosis: an international survey
por: Margineanu, Ioana, et al.
Publicado: (2022)

Tuberculosis prevention must integrate technological and basic care innovation
por: Mason, Paul H., et al.
Publicado: (2016)

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union
por: van der Werf, Marieke J., et al.
Publicado: (2017)

Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe
por: Nikolayevskyy, Vladyslav, et al.
Publicado: (2021)

QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection
por: Saluzzo, Francesca, et al.
Publicado: (2022)

Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
por: Chang, Chia‐Hao, et al.
Publicado: (2017)

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region
por: Blok, Nick, et al.
Publicado: (2016)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region
por: Chiang, Chen-Yuan, et al.
Publicado: (2020)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
por: Guglielmetti, Lorenzo, et al.
Publicado: (2022)

Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience
por: Sinkou, Heorhi, et al.
Publicado: (2017)

Impact of the SARS-CoV-2 epidemic on tuberculosis treatment outcome in Northern Italy
por: Magro, Paola, et al.
Publicado: (2020)

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases
por: Tadolini, Marina, et al.
Publicado: (2020)

Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital
por: Stochino, Claudia, et al.
Publicado: (2020)

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis
por: Tornheim, Jeffrey A., et al.
Publicado: (2022)

Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study
por: Chang, Lih-Yu, et al.
Publicado: (2018)

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
por: Akkerman, Onno W., et al.
Publicado: (2018)

A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis
por: Gupta, Nitesh, et al.
Publicado: (2020)

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
por: Masini, Tiziana, et al.
Publicado: (2022)

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
por: Sotgiu, Giovanni, et al.
Publicado: (2015)

Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study
por: Gupta, Rishi K., et al.
Publicado: (2021)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study
por: Lee, Chih-Hsin, et al.
Publicado: (2013)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

Accuracy of whole-genome sequencing to determine recent tuberculosis transmission: an 11-year population-based study in Hamburg, Germany
por: Diel, Roland, et al.
Publicado: (2019)

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
por: Ndjeka, Norbert, et al.
Publicado: (2020)

Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China
por: Lu, Peng, et al.
Publicado: (2017)

Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV
por: Kerkhoff, Andrew D., et al.
Publicado: (2020)

Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community
por: Mori, Toru, et al.
Publicado: (2015)

In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient
por: Ghodousi, Arash, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c00vd612gm60erukot7h1bp1q0